ライフサイエンスコーパス: obstructive cardiomyopathy

1 ic improvement in patients with hypertrophic obstructive cardiomyopathy.

2 rs in patients with symptomatic hypertrophic obstructive cardiomyopathy.

3 with refractory symptoms due to hypertrophic obstructive cardiomyopathy.

4 nical symptoms in patients with hypertrophic obstructive cardiomyopathy.

5 atients with severe symptoms of hypertrophic obstructive cardiomyopathy.

6 the treatment of patients with hypertrophic obstructive cardiomyopathy.

7 rease gradient in patients with hypertrophic obstructive cardiomyopathy.

8 ients with severely symptomatic hypertrophic obstructive cardiomyopathy.

9 atic treatment of patients with hypertrophic obstructive cardiomyopathy.

10 l septal ablation treatment for hypertrophic obstructive cardiomyopathy, a human model of planned myo

11 ts with refractory, symptomatic hypertrophic obstructive cardiomyopathy and significant left ventricu

12 rome, neurocardiogenic syncope, hypertrophic obstructive cardiomyopathy, and cardiac resynchronisatio

13 re, certain types of arrhythmia, hypertropic obstructive cardiomyopathy, and in patients with prior m

14 eptal reduction for symptomatic hypertrophic obstructive cardiomyopathy at our institution.

15 ruction from aortic stenosis or hypertrophic obstructive cardiomyopathy but can also suggest the diag

16 ients with severely symptomatic hypertrophic obstructive cardiomyopathy can relieve symptoms and decr

17 improved clinical outcomes for hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy and h

18 Because hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, hear

19 Patients with hypertrophic obstructive cardiomyopathy have left ventricular (LV) di

20 LVOT) velocity in patients with hypertrophic obstructive cardiomyopathy (HCM).

21 T) obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM) both acutely and on a

22 Hypertrophic obstructive cardiomyopathy (HOCM) is characterized by le

23 ry are unknown in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoing extended tr

24 tomatic pediatric patients with hypertrophic obstructive cardiomyopathy (HOCM) unresponsive to medica

25 low-up results in patients with hypertrophic obstructive cardiomyopathy (HOCM) who underwent either p

26 ype negative), 10 patients with hypertrophic obstructive cardiomyopathy (HOCM), 10 patients with aort

27 nfarction (MI) in patients with hypertrophic obstructive cardiomyopathy (HOCM).

28 myectomy) for the treatment of hypertrophic obstructive cardiomyopathy (HOCM).

29 utic strategy for patients with hypertrophic obstructive cardiomyopathy (HOCM).

30 roves symptoms in patients with hypertrophic obstructive cardiomyopathy (HOCM).

31 al reduction therapy (NSRT) for hypertrophic obstructive cardiomyopathy (HOCM).

32 chamber pacing in patients with hypertrophic obstructive cardiomyopathy (HOCM).

33 nse to therapy in patients with hypertrophic obstructive cardiomyopathy (HOCM).

34 ing treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM).

35 tly responsible for symptoms in hypertrophic obstructive cardiomyopathy (HOCM).

36 myectomy (SM) for treatment of hypertrophic obstructive cardiomyopathy (HOCM).

37 cise tolerance in patients with hypertrophic obstructive cardiomyopathy (HOCM).

38 ficacy of surgical treatment of hypertrophic obstructive cardiomyopathy in patients who are severely

39 Hypertrophic obstructive cardiomyopathy is an inherited myocardial di

40 Hypertrophic obstructive cardiomyopathy patients (N = 874) who underw

41 Of 173 consecutive hypertrophic obstructive cardiomyopathy patients who underwent ASA, 3

42 eatment of medically refractory hypertrophic obstructive cardiomyopathy patients with severe outflow

43 in dynamic obstruction in most hypertrophic obstructive cardiomyopathy patients.

44 A subgroup of patients with hypertrophic obstructive cardiomyopathy remain severely symptomatic d

45 ients with severely symptomatic hypertrophic obstructive cardiomyopathy were entered into this trial

46 symptoms in most patients with hypertrophic obstructive cardiomyopathy who are severely symptomatic

47 atients 20 to 70 years old with hypertrophic obstructive cardiomyopathy who had surgical treatment be

48 inical outcome in patients with hypertrophic obstructive cardiomyopathy who undergo septal myectomy.

49 Fifty patients with hypertrophic obstructive cardiomyopathy who underwent nonsurgical sep

50 chain reaction in patients with hypertrophic obstructive cardiomyopathy who were undergoing transcoro

51 y for symptomatic patients with hypertrophic obstructive cardiomyopathy with persistence of the favor